Healthcare - Biotechnology - NASDAQ - US
$ 0.5497
-7.16 %
$ 93.6 M
Market Cap
-0.46
P/E
CASH FLOW STATEMENT
-117 M
OPERATING CASH FLOW
10.6 M
INVESTING CASH FLOW
71.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Seres Therapeutics, Inc.
| Net Income | -114 M |
| Depreciation & Amortization | 6.24 M |
| Capital Expenditures | -7.98 M |
| Stock-Based Compensation | 34.1 M |
| Change in Working Capital | -59 M |
| Others | 5.92 M |
| Free Cash Flow | -125 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||
| Net Income | (113.7) | (250.2) | (65.6) | (89.1) | (70.3) | (98.9) | (89.4) | (91.6) | (54.8) | (16.7) | (6.1) | (3.1) |
| Depreciation & Amortization | 6.2 | 6.6 | 5.9 | 6.6 | 7.6 | 7.9 | 7.3 | 4.2 | 0.7 | 0.2 | 88 K | 25 K |
| Deferred Income Tax | 0 | 0 | 2.5 | 0 | 0.1 | 0 | 0 | 0 | 7 K | 1.4 | 8 K | 28 K |
| Stock Based Compensation | 34.1 | 25.5 | 20.2 | 8.8 | 8.3 | 16.6 | 17.4 | 16.9 | 9.7 | 2.1 | 0.2 | 28 K |
| Other Operating Activities | 15.0 | 7.6 | 2.0 | 3.3 | 2.3 | (0.2) | (0.2) | (0.4) | 0.4 | 0.4 | 19 K | 28 K |
| Change in Working Capital | (59.0) | (18.4) | 41.5 | (23.2) | (24.6) | 11.8 | (10.6) | 114.8 | 3.1 | 2.3 | 0.5 | 0.1 |
| Cash From Operations | (117.4) | (228.8) | 6.7 | (93.6) | (76.5) | (62.9) | (75.5) | 43.9 | (40.8) | (10.4) | (5.3) | (2.9) |
| INVESTING CASH FLOW | ||||||||||||
| Capital Expenditures | (8.0) | (9.8) | (9.6) | (0.6) | (1.0) | (1.9) | (4.7) | (21.5) | (4.4) | (1.0) | (0.2) | (0.3) |
| Other Items | 18.6 | 92.2 | 73.7 | (158.3) | (29.5) | 114.3 | 61.7 | (44.0) | (132.8) | (0.1) | 10 K | 27 K |
| Cash From Investing Activities | 10.6 | 82.4 | 64.1 | (158.9) | (30.5) | 112.3 | 57.0 | (65.5) | (137.1) | (1.1) | (0.2) | (0.3) |
| FINANCING CASH FLOW | ||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | (0.2) | 33 K | 0 | 24 K | 0 | 0 | 0 |
| Total Debt Repaid | 50.5 | 25.7 | (0.9) | 19.9 | 25.0 | 0 | 0 | 0 | (2.6) | 1.6 | 0.9 | 0.5 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.0 | 2.7 | 2.1 | 14.9 | 16 K | 0.4 | 0.1 | 2.1 | (2.7) | 122.4 | 0 | 8.9 |
| Cash From Financing Activities | 71.7 | 129.6 | 1.2 | 303.4 | 86.2 | 0.3 | 83 K | 2.1 | 137.7 | 124.0 | 0.9 | 9.4 |
| CHANGE IN CASH | ||||||||||||
| Net Change In Cash | (35.1) | (16.8) | 72.0 | 50.9 | (20.8) | 49.7 | (18.5) | (19.4) | (40.3) | 112.5 | (4.6) | 6.2 |
| FREE CASH FLOW | ||||||||||||
| Free Cash Flow | (125.3) | (238.6) | (2.9) | (94.2) | (77.5) | (64.8) | (80.2) | 22.4 | (45.2) | (11.4) | (5.5) | (3.2) |